Ms. Crain is the Chief Operating Officer of Moelis & Company and will chair the company’s audit committee
Ben Taylor, Exscientia’s Chief Financial Officer, also appointed to the Board
OXFORD – Exscientia the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has appointed Elizabeth Crain to its Board of Directors. Elizabeth will Chair Exscientia’s audit committee as well as help guide the company’s finance, market positioning and governance activities.
Elizabeth is the Chief Operating Officer and a Director of Moelis & Company where she leads firmwide strategy and the management of the global business, operations and risk functions.
Elizabeth has over 30 years’ experience in banking, investment and operating roles and has been named one of the "25 Most Powerful Women in Finance" by American Banker magazine. After 20 years at U.S. and European investment banks, Elizabeth became one of the founding partners of Moelis & Company and led the firm’s IPO. She also serves in trustee or advisory positions for The Wharton School, The Royal Academy Trust and the Global Futures Council of the World Economic Forum.
Andrew Hopkins CEO of Exscientia said, “Elizabeth brings incredible corporate and market perspective to our company. We have been doubling our operations every year since inception and she knows what it takes to achieve growth while maintaining culture, discipline and focus. Elizabeth will also be a tremendous advisor as we extend our presence with the investor community and expand our U.S. operations. I’m delighted to be strengthening the board, both with her appointment and the addition of Ben Taylor our Chief Financial Officer as an Executive Director”
Elizabeth Crain added, “To work with one of the fastest growing innovators in biotech is extremely exciting. It is clear Exscientia is transforming drug discovery and has the potential to bring breakthroughs to patients far faster than historically possible.”
Exscientia is an Artificial Intelligence (AI)-driven pharmatech, committed to discovering medicines in the fastest and most effective manner for patients. As a clinical stage company, Exscientia is the first to progress AI-designed small molecules into a clinical setting, demonstrating the ability of AI to transform the pharmaceutical industry.
Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.
Exscientia puts AI at the centre of its strategy to revolutionise drug discovery, designing therapeutics for areas of high unmet need, that will positively impact patients.
About Centaur Chemist®
Centaur Chemist® is Exscientia’s solution to AI-driven drug design combining the latest AI-tech with the therapeutic experience of seasoned drug hunters. Driven by algorithms that mimic evolutionary design as well as deep learning to analyse complex information and active learning to extract insights from sparse, high-value datasets, Centaur Chemist® has been skilfully engineered to work with widest range of discovery data to ensure application to the widest range of discovery projects.
Centaur Biologist® supports the discovery and prioritisation of drug targets, ensuring that any candidate molecules developed will be aligned with key therapeutic objectives. With deep learning and vector embedding techniques Centaur Biologist® pinpoints trends and insights from big data and captures semantics that predict new unexpected associations.
For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI
P: +44 (0)78 9685 9386
P: +44 (0)75 8300 3417
Mark Swindells, Chief Commercial Officer